Abstract 1431P
Background
Neoadjuvant chemotherapy combined with immunotherapy (nCIT) is emerging as a promising strategy for treating patients with esophageal cancer. We aimed to develop a novel, voxel-level radiomics deep learning model to predict the pathological complete response (pCR) to nCIT in esophageal squamous cell carcinoma (ESCC).
Methods
We included 745 ESCC patients from three institutions, comprising a training set (N=500, institution 1), test-set-1 (N=86, institution 1), test-set-2 (N=34, institution 2), and test-set-3 (N=125, institution 3). All patients underwent nCIT and received a pathological evaluation post-surgery. A total of 104 distinct radiomic features were extracted from the tumor areas in CT images prior to nCIT. Features demonstrating predictive power with an area under the receiver operating characteristic curve (AUROC) exceeding 0.6 were retained. Each selected radiomics feature map, along with the original image, was input into a vision transformer model as a separate channel. The Shapley Additive exPlanations method was employed to visualize feature importance and identify predictive regions within the tumor, enhancing the model’s interpretability. For baseline comparison, we also constructed a clinical model using only clinical factors, and compared it against traditional radiomics and ResNet models.
Results
The voxel-level radiomics deep learning model achieved an AUC of 0.825 with an accuracy of 76.2% in test-set-1, 0.751 and 68.5% in test-set-2, and 0.819 with 78.1% in test-set-3, respectively. It demonstrated superior predictive performance compared to the clinical model, traditional radiomics model, and ResNet model.
Conclusions
This innovative and noninvasive voxel-level radiomics deep learning approach offers an efficient and accurate approach of predicting treatment response to nCIT in ESCC, potentially benefiting clinical decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1164P - The influence of neoadjuvant radiotherapy on surgical management and prognostic outcomes in locally advanced rectal neuroendocrine carcinoma
Presenter: Weiran Xu
Session: Poster session 17
1165P - The significance and indications for lymphadenectomy in pancreatic neuroendocrine neoplasms
Presenter: Yosuke Uematsu
Session: Poster session 17
1166P - 21-day modified CAPTEM protocol is effective and safe for patients with advanced well-differentiated grade 1/2 pancreatic neuroendocrine tumors
Presenter: Nomi Bezalel Engelberg
Session: Poster session 17
1167P - Outcomes of local and systemic treatment in primary hepatic neuroendocrine neoplasms (PHNEN)
Presenter: Leonidas Apostolidis
Session: Poster session 17
1169P - Clustering of patients with lung neuroendocrine neoplasms using machine learning and its association with survival: A population based study from the U.S. SEER database
Presenter: Mohamed Mortagy
Session: Poster session 17
1170P - Convergent and divergent determinants of heterogeneity, biomarkers, and plasticity in thoracic and prostate neuroendocrine tumors
Presenter: Triparna Sen
Session: Poster session 17
Resources:
Abstract
1403P - A phase II study of tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: Long-term follow-up outcomes of TD-NICE
Presenter: Tao Jiang
Session: Poster session 17
1404P - Predictive role of circulating cytokines in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD1 inhibitor: Pooled analyses of two phase II clinical trials
Presenter: Baoqing Chen
Session: Poster session 17
1405P - Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for esophageal squamous cell carcinoma (EC-CRT-001 phase II trial)
Presenter: Ruixi Wang
Session: Poster session 17
Resources:
Abstract